Cost-effectiveness chronic lymphocytic leukaemia treatment
Research Project | 01.02.2020 - 30.06.2021
|
01.02.2020
- 30.06.2021
Funding
Cost-effectiveness of venetoclax in chronic lymphocytic leukaemia treatment
Abbvie AG, 04.2020-08.2021 (17)
PI : Schwenkglenks, Matthias.
Publications
Barbier, Michaela et al. (2021) ‘Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland’, The European journal of health economics : HEPAC : health economics in prevention and care, p. DOI: 10.1007/s10198–021–01398–7. Available at: https://doi.org/10.1007/s10198-021-01398-7.
Barbier, Michaela et al. (2021) ‘Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland’, The European journal of health economics : HEPAC : health economics in prevention and care, p. DOI: 10.1007/s10198–021–01398–7. Available at: https://doi.org/10.1007/s10198-021-01398-7.
Members (2)
Matthias Schwenkglenks
Principal Investigator
